As a result, GLP-1 medications are FDA-approved specifically for chronic weight management, and are recommended by major medical organizations as part of a comprehensive weight loss program
The bottom line: GLP-1 microdosing represents a shift toward more personalized, patient-centered weight management
B12 deficiency is a known concern with long-term GLP-1 therapy, particularly because many researchers are simultaneously reducing their caloric intake
Semaglutide (Wegovy, Ozempic) is generally considered safe for kidney function when used as prescribed
When expanding trial eligibility criteria to reflect broader patient populations typically encountered in clinical practice, we identified 453,201 individuals initiating semaglutide or sitagliptin (expanding SUSTAIN-6 eligibility) and 136,089 initiating tirzepatide or dulaglutide (expanding SURPASS-CVOT eligibility)